News » Visby Medical Appoints Industry Veteran John W. Kuo as Chief Legal Officer

10/21/2021Press Release

Visby Medical Appoints Industry Veteran John W. Kuo as Chief Legal Officer

Visby Medical™, a leading medical diagnostic company, today announced the appointment of John W. Kuo as the company’s new Chief Legal Officer. An experienced veteran in corporate law, Kuo brings more than 30 years of experience across multiple industries, including nearly 20 years in the healthcare industry.

Visby Medical Appoints Industry Veteran John W. Kuo as Chief Legal Officer

(SAN JOSE, CA), October 21, 2021Visby Medical™, a leading medical diagnostic company, today announced the appointment of John W. Kuo as the company’s new Chief Legal Officer. An experienced veteran in corporate law, Kuo brings more than 30 years of experience across multiple industries, including nearly 20 years in the healthcare industry. In his new role, Kuo will lead legal strategy on all corporate initiatives and provide counsel to the executive leadership team and board of directors.

“I am pleased to welcome John to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda. “Our company has grown exponentially since launching our flagship COVID-19 and Women’s Sexual Health diagnostics, and John’s expertise will be an invaluable asset to the company as we move forward.”

Most recently, Kuo served as Executive Vice President of General Counsel and Chief Compliance Officer at Charles River Laboratories where he was responsible for overseeing legal, compliance, privacy, regulatory and security functions.  Previously, he was Senior Vice President, General Counsel and Corporate Secretary at Varian Medical Systems for over 15 years.  Prior to that, he held leadership positions at BroadVision and 3Com Corporation.  He also serves as the board for Mirion Technologies and several non-profit boards, including UC Berkeley Law’s Alumni Association, the Law Foundation of Silicon Valley, the Asian Pacific Fund and the Cornell University Council.

“Visby’s proprietary technology has the potential to be a real-world solution for diagnosing and treating infectious diseases,” said Kuo. “I look forward to playing an essential role in an organization focused on accelerating the field of diagnostics.”

Kuo has been recognized with multiple awards, including “Lifetime Achievement Award” by the Silicon Valley Business Journal, “Legal Department of the Year” by The Recorder and “Legend in Law” by the Burton Foundation. He began practicing law as an associate attorney with Norton Rose Fulbright in Houston after attending UC Berkeley School of Law and Cornell University.

About Visby Medical™

Visby Medical is a diagnostics company that is transforming the order of diagnosis and treatment for infectious diseases. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedIn at www.linkedin.com/company/visbymedical; Facebook, Instagram, and Twitter @VisbyMedical.

Contact: (240) 839-0945 | press@visby.com

Read more articles & insights

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs

03/07/2024Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test